Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Locally Directed Therapy
BEHAVIORAL
2 trials
Sponsors
National Cancer Institute (NCI)
, Melek Nur KEÇELİ
Conditions
Adenocarcinoma of the Colon
Postpartum Women
Stage III Colon Cancer
Phase 3
Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer
Completed
NCT00079274
National Cancer Institute (NCI)
Adenocarcinoma of the Colon, Stage III Colon Cancer
Start: 2004-02-01
End: 2012-11-01
Updated: 2026-06-23
Unknown Phase
Effect of Foot Massage Performed to the Mother After Bırth on Breastfeedıng Success, Sleep Qualıty and Newborn Stress
Active, not recruiting
NCT06786481
Melek Nur KEÇELİ
Postpartum Women
Start: 2025-01-01
End: 2025-08-30
Target: 70
Updated: 2025-01-22
Related Papers
Pathological analysis of tumor microenvironmental features using deep learning to predict survival of colon carcinomas.
Journal of Clinical Oncology
2023-06-01
1 citations
Artificial intelligence–derived immune phenotypes for prediction of prognosis in patients with stage III colon cancer (NCCTG N0147; Alliance).
Journal of Clinical Oncology
2023-06-01
Association of tumor-infiltrating lymphocytes with survival depends on primary tumor sidedness in stage III colon cancers (NCCTG N0147) [Alliance].
2022-08-10
17 citations
Effect of primary tumor sidedness on the association of tumor-infiltrating lymphocytes with survival of patients with stage III colon cancer (NCCTG N0147) [alliance].
Journal of Clinical Oncology
2022-06-01
Can synthetic data be a proxy for real clinical trial data? A validation study
BMJ Open
2021-04-01
95 citations
Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147) (Alliance).
2020-01-25
48 citations
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
2020-01-16
25 citations
Genetic Variant Associated With Survival of Patients With Stage II-III Colon Cancer.
2019-12-04
9 citations
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies
Annals of Oncology
2019-07-01
130 citations
Relative contribution of clinical and molecular features to outcome within low and high risk T and N groups in stage III colon cancer (CC).
Journal of Clinical Oncology
2019-05-20
6 citations
Is the predictive and prognostic impact of sporadic and familial microsatellite instable stage III colon cancer different? A pooled analysis of the PETACC8 and NCCTG N0147 (Alliance) trials.
Journal of Clinical Oncology
2019-05-20
Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy
JAMA Oncology
2017-10-05
144 citations
Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy: NCCTG N0147 (Alliance).
Journal of Clinical Oncology
2017-05-20
3 citations
Genetic correlates of therapeutic toxicities of stage III colon carcinoma patients treated with adjuvant FOLFOX+/-cetuximab (NCCTG N0147, Alliance).
Journal of Clinical Oncology
2017-05-20
Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study.
2017-05-01
169 citations
Association of DNA Mismatch Repair and Mutations in <i>BRAF</i> and <i>KRAS</i> With Survival After Recurrence in Stage III Colon Cancers
JAMA Oncology
2016-12-22
93 citations
Molecular markers and survival after recurrence in stage III colon cancers from NCCTG N0147 and NSABP C-08 adjuvant chemotherapy trials.
Journal of Clinical Oncology
2016-05-20
1 citations
Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients (pts) treated with adjuvant FOLFOX +/- cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials.
Journal of Clinical Oncology
2015-05-20
5 citations
Influence of molecular alterations on site-specific (ss) time to recurrence (TTR) following adjuvant therapy in resected colon cancer (CC) (Alliance Trial N0147).
Journal of Clinical Oncology
2015-05-20
3 citations
Overall survival result and outcomes by <i>KRAS</i>, <i>BRAF</i>, andDNA mismatch repair in relation to primary tumor site in colon cancers from a randomized trial of adjuvant chemotherapy: NCCTG (Alliance) N0147.
Journal of Clinical Oncology
2014-05-20
12 citations
1 more papers not shown